News and Resources from the WTWH Media Life Science Network - Page 967 of 968

Gilead licenses remdesivir production to 5 generic drugmakers

Gilead Sciences’ (NSDQ:GILD) said Tuesday that it has signed licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir, the experimental drug being used in the U.S. to treat COVID-19.

The non-exclusive, voluntary agreements allow the companies — Mylan (NSDQ:MYL), Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences — to manufacture remdesivir for distribution in 127 countries. The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access, according to Foster City, Calif.-based Gilead.

Get the full story on our sister site, MassDevice.

Gilead licenses remdesivir production to 5 generic drugmakers

(Image from Gilead Sciences)

Gilead Sciences’ (NSDQ:GILD) said Tuesday that it has signed licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir, the experimental drug being used in the U.S. to treat COVID-19.

The non-exclusive, voluntary agreements allow the companies — Mylan (NSDQ:MYL), Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences — to manufacture remdesivir for distribution in 127 countries. The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access, according to Foster City, Calif.-based Gilead.

The FDA gave remdesivir emergency use authorization May 1. State health departments are distributing it within their states.

Remdesivir is an intravenous drug that…

Molex taps former Ecolab SVP to run its medical business, including Phillips-Medisize

Paul Chaffin, SVP of Molex’s Medical and Pharmaceutical Solutions division

Paul Chaffin — most recently SVP of enterprise initiatives at Ecolab — has become SVP in charge of Molex’s Medical and Pharmaceutical Solutions division, including contract manufacturing giant Phillips-Medisize.

Chaffin will report to Molex CEO Joe Nelligan and will be a member of the company’s Global Leadership Team.

“Paul’s depth of healthcare, commercial and international experience combined with his strong leadership skills will be a big asset to not only our medical business but to the Molex leadership team. We’re confident that Paul will help fulfill our vision of expanding our global footprint with innovative and digitally connected medical solutions at a time when delivering top-quality care to patients around the world is so critical,” said Joe Nelligan, CEO of Molex.

Chaffin described the combined…

Could COVID-19 be telehealth’s big moment?

Frost & Sullivan announced today that recent analysis finds that the demand for telehealth technology is expected to rise amid the COVID-19 pandemic.

The analysis, titled “Telehealth — A Technology-Based Weapon in the War Against the Coronavirus, 2020,” revealed that, as COVID-19 continues to disrupt the practice of medicine and the delivery of healthcare, the U.S. telehealth market will experience seven-fold growth by 2025.

Over the five-year period that the analysis looks at, the U.S. telehealth market could see a compound annual growth rate (CAGR) of 38.2%. This year alone, the analysts expect the market to experience year-over-year growth of 64.3%.

“The critical need for social distancing among physicians and patients will drive unprecedented demand for telehealth, which involves the use of communication systems and networks to enable either a synchronous or asynchronous session between the patient and provider,” Frost & Sullivan …

Could COVID-19 be telehealth’s big moment?

Frost & Sullivan announced today that recent analysis finds that the demand for telehealth technology is expected to rise amid the COVID-19 pandemic.

The analysis, titled “Telehealth — A Technology-Based Weapon in the War Against the Coronavirus, 2020,” revealed that, as COVID-19 continues to disrupt the practice of medicine and the delivery of healthcare, the U.S. telehealth market will experience seven-fold growth by 2025.

Over the five-year period that the analysis looks at, the U.S. telehealth market could see a compound annual growth rate (CAGR) of 38.2%. This year alone, the analysts expect the market to experience year-over-year growth of 64.3%.

“The critical need for social distancing among physicians and patients will drive unprecedented demand for telehealth, which involves the use of communication systems and networks to enable either a synchronous or asynchronous session between the patient and provider,” Frost & Sullivan …

Could COVID-19 be telehealth’s big moment?

Frost & Sullivan announced today that recent analysis finds that the demand for telehealth technology is expected to rise amid the COVID-19 pandemic.

The analysis, titled “Telehealth — A Technology-Based Weapon in the War Against the Coronavirus, 2020,” revealed that, as COVID-19 continues to disrupt the practice of medicine and the delivery of healthcare, the U.S. telehealth market will experience seven-fold growth by 2025.

Get the full story at our sister site, Medical Design & Outsourcing.

FDA labels Applied Medical catheter recall as Class I

The FDA announced yesterday that the Applied Medical recall of multiple kinds of its catheters is designated as Class I, the most serious type of recall.

The Python embolectomy catheters, Bard embolectomy catheters and the OTW Latis cleaning catheters were the types recalled by Applied Medical. A total of 19,400 devices were recalled in the U.S., having been manufactured between July 23, 2015, and Nov. 8, 2018, and distributed between Aug. 25, 2015, and March 1, 2019. The company initiated the recall on Oct. 24, 2019, according to an FDA release.

Get the full story at our sister site, MassDevice.

Philips lands 510(k) to market ultrasound systems for COVID-19

The FDA has granted Royal Philips (NYSE:PHG) 510(k) clearance to market a wide range of its ultrasound systems to help manage COVID-19-related lung and cardiac complications.

Handheld and portable ultrasound solutions in particular have become valuable tools for clinicians treating COVID-19 patients due to their imaging capabilities, portability and ease of disinfection, according to Philips.

The 510(k) clearance, which Philips called an industry first, allows the Netherlands-based company to provide detailed, practical guidance to support clinicians using its systems and software for COVID-19 patients. The clearance applies to Philips’ EPIQ series, Affiniti series, Lumify, CX50 and Sparq diagnostic ultrasound systems, and to off-cart solutions like QLAB advanced quantification software.

Ultrasound has shown value in imaging peripheral lung tissue affected by pneumonia, which is closely tied to COVID-19 lung complications, according to Philips. As …

DexCom prices $1.05B ‘upsized’ offering

Continuous glucose monitoring system developer Dexcom (NSDQ:DXCM) announced today that it priced an upsized offering worth $1.05 billion in convertible senior notes.

Yesterday, the San Diego-based company announced an offering worth $850 million with plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate principal amount of notes. Today, DexCom increased the aggregate principal amount and granted a 13-day option to purchase up to an additional $157.5 million in notes.

DexCom is offering senior, unsecured obligations with an interest rate of 0.25% per year. The notes will mature on Nov. 15, 2025. The company expects the sale of the notes to close on May 14, 2020, according to a news release.

Before 5 p.m. ET on the business day immediately preceding Aug. 15, 2025, the notes will be convertible at the option of the holders. Upon conversion, they may be settled in shares of DexCom’s common stock, cash, or a co…

Solar Atmospheres adds gas nitriding furnace

[Image courtesy of Solar Atmospheres]

Solar Atmospheres (Souderton Pa.) announced today that it has installed a new vacuum gas nitriding furnace — built by its sister company, Solar Manufacturing.

The front-loading furnace incorporates the latest nitriding and recipe system from Solar Manufacturing. The automated controls meet AMS2759/10, Automated Gaseous Nitriding Controlled by Nitrogen Potential, in addition to the standard AMS2759/6, Gaseous Nitriding of Low-Alloy Steel Parts.

The automated control system is useful for single-stage, as well as two-stage (Floe) processing. All hot zone components are made completely of graphitic materials inert to the anhydrous ammonia used during the nitriding process.

In addition to a forced gas cooling system, the furnace also incorporates Solar Manufacturing’s convection heating system. This design has significant advantages over conventional retort-type sy…

New imaging tech allows visualization of nanoscale structures

This image shows a 3D super-resolution reconstruction of dendrites in primary visual cortex.

Since Robert Hooke’s first description of a cell in Micrographia 350 years ago, microscopy has played an important role in understanding the rules of life.

However, the smallest resolvable feature, the resolution, is restricted by the wave nature of light. This century-old barrier has restricted understanding of cellular functions, interactions and dynamics, particularly at the sub-micron to nanometer scale.

Super-resolution fluorescence microscopy overcomes this fundamental limit, offering up to tenfold improvement in resolution, and allows scientists to visualize the inner workings of cells and biomolecules at unprecedented spatial resolution.

Such resolving capability is impeded, however, when observing inside whole-cell or tissue specimens, such as the ones often analyzed during the studies of the …

FDA clears Transit Scientific peripheral vasculature microcatheter

[Image from Transit Scientific]Transit Scientific today said it won FDA clearance for its XO Cross Microvatheter platform.

XO Cross Microcatheter is designed for guidewire support, exchange and contrast media injection in the peripheral vasculature.

Microcatheters are small 0.70-1.30mm diameter catheters that are used for guidewire support, exchanges, to access distal anatomy, cross lesions, deliver therapeutic embolic, inject contrast media and perform other procedures in complex endovascular procedures.

“We use multiple microcatheters every day,” interventional cardiologist George Adams said in a news release. “Improving access to distal vasculature is important. We are performing more radial procedures too and need long, responsive, and fatigue-resistant microcatheter technology.”

Transit Scientific’s XO Cross Microcatheter platform delivers new levels of pushability, traceability, flexibility and torque response t…